Vaxart Reconciled Depreciation vs Ebit Analysis
VXRT Stock | USD 0.60 0.01 1.64% |
Vaxart financial indicator trend analysis is much more than just breaking down Vaxart Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxart Inc is a good investment. Please check the relationship between Vaxart Reconciled Depreciation and its Ebit accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Reconciled Depreciation vs Ebit
Reconciled Depreciation vs Ebit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxart Inc Reconciled Depreciation account and Ebit. At this time, the significance of the direction appears to have pay attention.
The correlation between Vaxart's Reconciled Depreciation and Ebit is -0.81. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Ebit in the same time period over historical financial statements of Vaxart Inc, assuming nothing else is changed. The correlation between historical values of Vaxart's Reconciled Depreciation and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Vaxart Inc are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Reconciled Depreciation i.e., Vaxart's Reconciled Depreciation and Ebit go up and down completely randomly.
Correlation Coefficient | -0.81 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Reconciled Depreciation
Ebit
Most indicators from Vaxart's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxart Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Enterprise Value is likely to gain to about 127.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.2 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 70.6M | 110.4M | 90.7M | 95.3M | Cost Of Revenue | 48.7M | 3.3M | 68.1M | 53.4M |
Vaxart fundamental ratios Correlations
Click cells to compare fundamentals
Vaxart Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vaxart fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 37.0M | 152.6M | 221.2M | 153.8M | 91.8M | 150.6M | |
Short Long Term Debt Total | 2.3M | 7.2M | 13.0M | 21.7M | 26.5M | 29.3M | |
Other Current Liab | 2.9M | 7.6M | 5.9M | 8.2M | 5.6M | 9.8M | |
Total Current Liabilities | 9.2M | 11.8M | 10.8M | 17.9M | 13.7M | 17.6M | |
Total Stockholder Equity | 13.0M | 123.4M | 187.5M | 110.6M | 57.8M | 89.3M | |
Property Plant And Equipment Net | 2.2M | 8.3M | 19.8M | 41.3M | 36.6M | 27.5M | |
Net Debt | (11.2M) | (119.7M) | (130.7M) | (22.3M) | (8.2M) | (8.7M) | |
Retained Earnings | (116.7M) | (148.9M) | (219.4M) | (327.1M) | (409.6M) | (389.1M) | |
Cash | 13.5M | 126.9M | 143.7M | 44.0M | 34.8M | 52.2M | |
Non Current Assets Total | 19.4M | 24.1M | 52.0M | 54.4M | 46.3M | 40.4M | |
Non Currrent Assets Other | 141K | 372K | 890K | 3.6M | 926K | 879.7K | |
Cash And Short Term Investments | 13.5M | 126.9M | 166.5M | 93.7M | 39.7M | 61.2M | |
Net Receivables | 3.6M | 334K | 71K | 20K | 3.0M | 2.9M | |
Common Stock Shares Outstanding | 21.6M | 88.3M | 121.5M | 127.7M | 144.8M | 152.1M | |
Liabilities And Stockholders Equity | 37.0M | 152.6M | 221.2M | 153.8M | 91.8M | 150.6M | |
Non Current Liabilities Total | 14.9M | 17.4M | 22.9M | 25.3M | 20.3M | 27.5M | |
Other Current Assets | 453K | 2.4M | 5.2M | 3.7M | 2.8M | 4.7M | |
Other Stockholder Equity | 129.6M | 272.3M | 406.9M | 438.0M | 467.4M | 490.7M | |
Total Liab | 24.1M | 29.2M | 33.6M | 43.3M | 34.0M | 44.6M | |
Property Plant And Equipment Gross | 2.2M | 8.3M | 19.8M | 15.6M | 43.4M | 24.7M | |
Total Current Assets | 17.6M | 128.5M | 169.2M | 99.5M | 45.5M | 43.3M | |
Accumulated Other Comprehensive Income | (1.6M) | (459K) | (74K) | (299K) | (1K) | (1.1K) | |
Short Term Debt | 841K | 2.1M | 1.0M | 2.3M | 6.5M | 6.8M | |
Intangible Assets | 17.1M | 15.4M | 10.6M | 5.0M | 4.3M | 4.1M | |
Accounts Payable | 852K | 2.1M | 3.9M | 5.5M | 1.6M | 1.5M | |
Common Stock Total Equity | 714K | 4.8M | 11K | 13K | 11.7K | 11.1K | |
Common Stock | 714K | 5K | 11K | 13K | 15K | 14.3K | |
Current Deferred Revenue | 4.6M | 4.2M | 5.1M | 2M | 1.8M | 1.7M | |
Other Liab | 13.4M | 14.9M | 10.9M | 5.9M | 6.7M | 7.9M | |
Net Tangible Assets | 13.0M | 123.4M | 187.5M | 110.6M | 127.2M | 67.4M | |
Other Assets | 141K | 372K | 890K | 3.6M | 4.1M | 4.3M | |
Retained Earnings Total Equity | (116.7M) | (148.9M) | (219.4M) | (327.1M) | (294.4M) | (279.7M) | |
Capital Surpluse | 124.8M | 272.3M | 406.9M | 438.0M | 503.7M | 528.9M | |
Property Plant Equipment | 210K | 1.5M | 6.6M | 15.6M | 17.9M | 18.8M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.